These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17380065)

  • 1. Pharmacological treatment of diabetic retinopathy.
    Lang GE
    Ophthalmologica; 2007; 221(2):112-7. PubMed ID: 17380065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of diabetic retinopathy with protein kinase C subtype Beta inhibitor.
    Lang GE
    Dev Ophthalmol; 2007; 39():157-165. PubMed ID: 17245085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of protein kinase C in the pathophysiology of diabetic retinopathy].
    Lang GE; Kampmeier J
    Klin Monbl Augenheilkd; 2002 Nov; 219(11):769-76. PubMed ID: 12494366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin in diabetic retinopathy.
    Croxen R; Baarsma GS; Kuijpers RW; van Hagen PM
    Pediatr Endocrinol Rev; 2004 Aug; 1 Suppl 3():518-24. PubMed ID: 16444186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological treatment of diabetic retinopathy].
    Lang GE
    Ophthalmologe; 2004 Dec; 101(12):1165-70. PubMed ID: 15592846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current approaches and perspectives in the medical treatment of diabetic retinopathy.
    Porta M; Allione A
    Pharmacol Ther; 2004 Aug; 103(2):167-77. PubMed ID: 15369682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of somatostatin receptor ligands in obesity and diabetic complications.
    Boehm BO; Lustig RH
    Best Pract Res Clin Gastroenterol; 2002 Jun; 16(3):493-509. PubMed ID: 12079271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors.
    Davis MI; Wilson SH; Grant MB
    Horm Metab Res; 2001 May; 33(5):295-9. PubMed ID: 11440276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.
    Budhiraja S; Singh J
    Fundam Clin Pharmacol; 2008 Jun; 22(3):231-40. PubMed ID: 18485142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of protein kinase C might be harmful to diabetic retinopathy.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2004; 63(1):135-7. PubMed ID: 15193366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKC inhibition and diabetic microvascular complications.
    Clarke M; Dodson PM
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy.
    Curtis TM; Scholfield CN
    Diabetes Metab Res Rev; 2004; 20(1):28-43. PubMed ID: 14737743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in biochemical mechanisms of diabetic retinopathy.
    Giusti C; Gargiulo P
    Eur Rev Med Pharmacol Sci; 2007; 11(3):155-63. PubMed ID: 17970231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of diabetic retinopathy with somatostatin analogues].
    Lang GE
    Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing paradigms in the treatment of diabetic retinopathy.
    El-Asrar AM; Al-Mezaine HS; Ola MS
    Curr Opin Ophthalmol; 2009 Nov; 20(6):532-8. PubMed ID: 19644368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific medical intervention for diabetic retinopathy.
    Ng JS
    Med Hypotheses; 2009 Aug; 73(2):158-60. PubMed ID: 19380207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
    Danis RP; Sheetz MJ
    Expert Opin Pharmacother; 2009 Dec; 10(17):2913-25. PubMed ID: 19929710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and future pharmacological intervention for diabetic retinopathy.
    Comer GM; Ciulla TA
    Expert Opin Emerg Drugs; 2005 May; 10(2):441-55. PubMed ID: 15934878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of modulation of GH/IGF-I axis in the development of diabetic proliferative retinopathy.
    Genovese S; Riccardi G
    J Endocrinol Invest; 2003; 26(8 Suppl):114-6. PubMed ID: 15233225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.